These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 8131484

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major.
    Wu KH, Chang JS, Tsai CH, Peng CT.
    Ann Hematol; 2004 Jul; 83(7):471-3. PubMed ID: 14658011
    [Abstract] [Full Text] [Related]

  • 5. Successful recovery of acute hemosiderotic heart failure in beta-thalassemia major treated with a combined regimen of desferrioxamine and deferiprone.
    Tavecchia L, Masera N, Russo P, Cirò A, Vincenzi A, Vimercati C, Masera G.
    Haematologica; 2006 Jun; 91(6 Suppl):ECR19. PubMed ID: 16785138
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
    Kolnagou A, Kontoghiorghes GJ.
    Hemoglobin; 2006 Jun; 30(2):239-49. PubMed ID: 16798649
    [Abstract] [Full Text] [Related]

  • 8. Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients.
    Cassinerio E, Roghi A, Pedrotti P, Brevi F, Zanaboni L, Graziadei G, Pattoneri P, Milazzo A, Cappellini MD.
    Ann Hematol; 2012 Sep; 91(9):1443-9. PubMed ID: 22572843
    [Abstract] [Full Text] [Related]

  • 9. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
    Cassinerio E, Orofino N, Roghi A, Duca L, Poggiali E, Fraquelli M, Zanaboni L, Cappellini MD.
    Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
    [Abstract] [Full Text] [Related]

  • 10. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
    Wang CH, Wu KH, Tsai FJ, Peng CT, Tsai CH.
    Hemoglobin; 2006 Sep; 30(2):257-62. PubMed ID: 16798651
    [Abstract] [Full Text] [Related]

  • 11. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ.
    Circulation; 2007 Apr 10; 115(14):1876-84. PubMed ID: 17372174
    [Abstract] [Full Text] [Related]

  • 12. [Intensive intravenous chelation in thalassemic patients with iron overload].
    Di Gregorio F, Leonardi C, Sciuto C, Cannella A, Pizzarelli G.
    Minerva Pediatr; 1998 Mar 10; 50(3):81-5. PubMed ID: 9676102
    [Abstract] [Full Text] [Related]

  • 13. Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2 and T2*.
    Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2006 Mar 10; 30(2):219-27. PubMed ID: 16798647
    [Abstract] [Full Text] [Related]

  • 14. Acute renal failure occurring during intravenous desferrioxamine therapy: recovery after haemodialysis.
    Cianciulli P, Sorrentino F, Forte L, Palombi M, Papa G, Meloni C, Taccone Gallucci M, Casciani CU.
    Haematologica; 1992 Mar 10; 77(6):514-5. PubMed ID: 1289188
    [Abstract] [Full Text] [Related]

  • 15. Intravenous chelation therapy during transplantation for thalassemia.
    Gaziev D, Giardini C, Angelucci E, Polchi P, Galimberti M, Baronciani D, Erer B, Maiello A, Lucarelli G.
    Haematologica; 1995 Mar 10; 80(4):300-4. PubMed ID: 7590497
    [Abstract] [Full Text] [Related]

  • 16. [Magnetic resonance imaging evidence of the effectiveness of combination chelation therapy in iron overload cardiomyopathy].
    Martín M, Estornell J, Orero M, Pérez JL, Ridocci F, Martínez V.
    Rev Esp Cardiol; 2006 Jan 10; 59(1):75-7. PubMed ID: 16434009
    [Abstract] [Full Text] [Related]

  • 17. Prevention of heart disease by subcutaneous desferrioxamine in patients with thalassaemia major.
    Richardson ME, Matthews RN, Alison JF, Menahem S, Mitvalsky J, Byrt E, Harper RW.
    Aust N Z J Med; 1993 Dec 10; 23(6):656-61. PubMed ID: 8141693
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. High-dose deferoxamine treatment (intravenous) for thalassaemia patients with cardiac complications.
    Ghader FR, Kousarian M, Farzin D.
    East Mediterr Health J; 2007 Dec 10; 13(5):1053-9. PubMed ID: 18290397
    [Abstract] [Full Text] [Related]

  • 20. Transfusional hemosiderosis and combined chelation therapy in sickle thalassemia.
    Tsironi M, Polonifi K, Deftereos S, Farmakis D, Andriopoulos P, Moyssakis I, Aessopos A.
    Eur J Haematol; 2005 Oct 10; 75(4):355-8. PubMed ID: 16146544
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.